{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:56Z","timestamp":1761514856813,"version":"3.37.3"},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology of Vietnam","doi-asserted-by":"publisher","award":["104.01-2019.300"],"award-info":[{"award-number":["104.01-2019.300"]}],"id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Korean Government","doi-asserted-by":"publisher","award":["2017R1A5A2015541"],"award-info":[{"award-number":["2017R1A5A2015541"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Herein, we have designed and synthesized a series of the novel (E)-N'-((1-(4-chlorobenzyl)-1H-indol-3-yl)methylene)-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides (5) as potent small molecules activating procaspase-3. The compounds were designed by the amalgamation of structural features of PAC-1 (the first procaspase-3 activator) and oncrasin-1, one potential anticancer agent.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The target acetohydrazides (5a-m) were prepared via the Niementowski condensation of anthranilic acid (1a) or 5-substituted-2-aminobenzoic acid (1b-m) and formamide. The compound libraries were evaluated for their cytotoxicity, caspase-3 activation, cell cycle analysis, and apoptosis. In addition, computational chemistry is also performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A biological evaluation revealed that all thirteen compounds designed and synthesized showed strong cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer) with eight compounds (5a, 5c-i, 5k), which were clearly more potent than both PAC-1 and oncrasin-1. In this series, four compounds including 5c, 5e, 5f, and 5h, were the most potent members with approximately 4- to 5-fold stronger than the reference compounds PAC-1 and oncrasin-1 in terms of  IC50. In comparison to 5-FU, these compounds were even 18- to 29-fold more potent in terms of cytotoxicity in three human cell lines tested. In the caspase activation assay, the caspase activity was activated to 285% by compound 5e in comparison to PAC-1, the first procaspase activating compound, which was used as a control. Our docking simulation revealed that compound 5e was a potent allosteric inhibitor of procaspase-3 through chelation of inhibitory zinc ion. Physicochemical and ADMET calculations for 5e provided useful information of its suitable absorption profile and some toxicological effects that need further optimization to be developed as a promising anticancer agent.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Compound 5e has emerged as a potential hit for further design and development of caspases activators and anticancer agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520622666220118154914","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:07:50Z","timestamp":1642565270000},"page":"2586-2598","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis and Evaluation of Novel (E)-N'-((1-(4-chlorobenzyl)-1H-indol-3-\nyl)methylene)-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as Antitumor Agents"],"prefix":"10.2174","volume":"22","author":[{"given":"Do Thi Mai","family":"Dung","sequence":"first","affiliation":[{"name":"Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, 10000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Jae","family":"Park","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chungbuk National University,\n194-31, Osongsaengmyung-1, Heungdeok, Chungbuk, 28160, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duong Tien","family":"Anh","sequence":"additional","affiliation":[{"name":"Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, 10000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pham-The","family":"Hai","sequence":"additional","affiliation":[{"name":"Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, 10000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Quang","family":"Bao","sequence":"additional","affiliation":[{"name":"Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, 10000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Young","family":"Ji","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chungbuk National University,\n194-31, Osongsaengmyung-1, Heungdeok, Chungbuk, 28160, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Soon","family":"Kang","sequence":"additional","affiliation":[{"name":"Korea Research Institute of Bioscience and\nBiotechnology, Cheongju, Chungbuk, 28116, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-203X","authenticated-orcid":true,"given":"Truong Thanh","family":"Tung","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Phenikaa University, Hanoi 12116, Vietnam"},{"name":"PHENIKAA Institute for Advanced Study (PIAS), Phenikaa University, Hanoi 12116, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Bae","family":"Han","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chungbuk National University,\n194-31, Osongsaengmyung-1, Heungdeok, Chungbuk, 28160, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen-Hai","family":"Nam","sequence":"additional","affiliation":[{"name":"Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, 10000, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/13543776.2018.1432596","volume":"28","author":"Hameed A.","year":"2018","unstructured":"Hameed A.; Al-Rashida M.; Uroos M.; Ali S.A.; Arshia M.; Ishtiaq M.; Khan K.M.; Quinazoline and quinazolinone as im-portant me-dicinal scaffolds: A comparative patent review (2011-2016). Expert Opin Ther Pat 2018,28(4),281-297","journal-title":"Expert Opin Ther Pat"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"395637","DOI":"10.1155\/2014\/395637","volume":"2014","author":"Asif M.","year":"2014","unstructured":"Asif M.; Chemical characteristics, synthetic methods, and biologi-cal potential of quinazoline and quinazolinone derivatives. Int J Med Chem 2014,2014,395637","journal-title":"Int J Med Chem"},{"key":"ref=3","first-page":"1206","volume":"6","author":"Srivastava S.","year":"2015","unstructured":"Srivastava S.; Srivastava S.; Biological activity of Quinazoline: A review. Int J Pharm Sci Res 2015,6,1206-1213","journal-title":"Int J Pharm Sci Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bioorg.2017.02.002","volume":"71","author":"Huong T-T-L.","year":"2017","unstructured":"Huong T-T-L.; Dung D-T-M.; Huan N-V.; Cuong L-V.; Hai P-T.; Huong L-T-T.; Kim J.; Kim Y-G.; Han S-B.; Nam N-H.; Novel N-hydroxybenzamides incorporating 2-oxoindoline with un-expected potent histone deacetylase inhibitory effects and anti-tumor cytotoxici-ty. Bioorg Chem 2017,71,160-169","journal-title":"Bioorg Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e1800027","DOI":"10.1002\/cbdv.201800027","volume":"15","author":"Hieu D.T.","year":"2018","unstructured":"Hieu D.T.; Anh D.T.; Hai P-T.; Huong L-T-T.; Park E.J.; Choi J.E.; Kang J.S.; Dung P.T.P.; Han S-B.; Nam N-H.; Quinazoline-based hydroxamic acids: Design, synthesis, and evaluation of his-tone deacetylase inhibitory effects and cytotoxicity. Chem Biodivers 2018,15(6),e1800027","journal-title":"Chem Biodivers"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e1800502","DOI":"10.1002\/cbdv.201800502","volume":"16","author":"Hieu D.T.","year":"2019","unstructured":"Hieu D.T.; Anh D.T.; Hai P-T.; Thuan N.T.; Huong L-T-T.; Park E.J.; Young Ji A.; Soon Kang J.; Phuong Dung P.T.; Han S-B.; Nam N-H.; Quinazolin-4(3H)-one-based hydroxamic acids: Design, synthesis and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chem Biodivers 2019,16(4),e1800502","journal-title":"Chem Biodivers"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN esti-mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd2662","volume":"7","author":"Storey S.","year":"2008","unstructured":"Storey S.; Targeting apoptosis: Selected anticancer strategies. Nat Rev Drug Discov 2008,7(12),971-972","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/1389450033346966","volume":"4","author":"Nam N.H.","year":"2003","unstructured":"Nam N.H.; Parang K.; Current targets for anticancer drug discov-ery. Curr Drug Targets 2003,4(2),159-179","journal-title":"Curr Drug Targets"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nchembio814","volume":"2","author":"Putt K.S.","year":"2006","unstructured":"Putt K.S.; Chen G.W.; Pearson J.M.; Sandhorst J.S.; Hoagland M.S.; Kwon J-T.; Hwang S-K.; Jin H.; Churchwell M.I.; Cho M-H.; Doerge D.R.; Helferich W.G.; Hergenrother P.J.; Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2006,2(10),543-550","journal-title":"Nat Chem Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1515\/BC.2004.034","volume":"385","author":"Krepela E.","year":"2004","unstructured":"Krepela E.; Proch\u00e1zka J.; Liul X.; Fiala P.; Kinkor Z.; Increased expression of Apaf-1 and procaspase-3 and the functionality of in-trinsic apoptosis apparatus in non-small cell lung carcinoma. Biol Chem 2004,385(2),153-168","journal-title":"Biol Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00008390-200108000-00009","volume":"11","author":"Fink D.","year":"2001","unstructured":"Fink D.; Schlagbauer-Wadl H.; Selzer E.; Lucas T.; Wolff K.; Pehamberger H.; Eichler H.G.; Jansen B.; Elevated procaspase levels in human melanoma. Melanoma Res 2001,11(4),385-393","journal-title":"Melanoma Res"},{"key":"ref=13","first-page":"738","volume":"9","author":"O\u2019Donovan N.","year":"2003","unstructured":"O\u2019Donovan N.; Crown J.; Stunell H.; Hill A.D.K.; McDermott E.; O\u2019Higgins N.; Duffy M.J.; Caspase 3 in breast cancer. Clin Cancer Res 2003,9(2),738-742","journal-title":"Clin Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/modpathol.3800146","volume":"17","author":"Persad R.","year":"2004","unstructured":"Persad R.; Liu C.; Wu T-T.; Houlihan P.S.; Hamilton S.R.; Diehl A.M.; Rashid A.; Overexpression of caspase-3 in hepatocel-lular carcinomas. Mod Pathol 2004,17(7),861-867","journal-title":"Mod Pathol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0002-9440(10)65398-9","volume":"154","author":"Izban K.F.","year":"1999","unstructured":"Izban K.F.; Wrone-Smith T.; Hsi E.D.; Schnitzer B.; Quevedo M.E.; Alkan S.; Characterization of the interleukin-1\u03b2-converting en-zyme\/ced-3-family protease, caspase-3\/CPP32, in Hodgkin\u2019s disease: Lack of caspase-3 expression in nodular lymphocyte pre-dominance Hodgkin\u2019s disease. Am J Pathol 1999,154(5),1439-1447","journal-title":"Am J Pathol"},{"key":"ref=16","first-page":"4578","volume":"57","author":"Nakagawara A.","year":"1997","unstructured":"Nakagawara A.; Nakamura Y.; Ikeda H.; Hiwasa T.; Kuida K.; Su M.S-S.; Zhao H.; Cnaan A.; Sakiyama S.; High levels of ex-pression and nuclear localization of interleukin-1 \u03b2 converting en-zyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 1997,57(20),4578-4584","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1158\/1078-0432.CCR-0778-02","volume":"10","author":"Svingen P.A.","year":"2004","unstructured":"Svingen P.A.; Loegering D.; Rodriquez J.; Meng X.W.; Mesner P.W.; Holbeck S.; Monks A.; Krajewski S.; Scudiero D.A.; Sausville E.A.; Reed J.C.; Lazebnik Y.A.; Kaufmann S.H.; Com-ponents of the cell death machine and drug sensitivity of the Na-tional Cancer Institute Cell Line Panel. Clin Cancer Res 2004,10(20),6807-6820","journal-title":"Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/0929867323666151127201829","volume":"23","author":"Roth H.S.","year":"2016","unstructured":"Roth H.S.; Hergenrother P.J.; Derivatives of procaspase-activating compound 1 (PAC-1) and their anticancer activities. Curr Med Chem 2016,23(3),201-241","journal-title":"Curr Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1039\/c0dt01590c","volume":"40","author":"Peng X.","year":"2011","unstructured":"Peng X.; Tang X.; Qin W.; Dou W.; Guo Y.; Zheng J.; Liu W.; Wang D.; Aroylhydrazone derivative as fluorescent sensor for highly selective recognition of Zn2+ ions: Syntheses, characteriza-tion, crystal structures and spectroscopic properties. Dalton Trans 2011,40(19),5271-5277","journal-title":"Dalton Trans"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14756366.2018.1555536","volume":"34","author":"Huan L.C.","year":"2019","unstructured":"Huan L.C.; Phuong C.V.; Truc L.C.; Thanh V.N.; Pham-The H.; Huong L-T-T.; Thuan N.T.; Park E.J.; Ji A.Y.; Kang J.S.; Han S-B.; Tran P-T.; Nam N-H.; (E)-N\u2032-Arylidene-2-(4-oxoquinazolin-4(3H)-yl) acetohydrazides: Synthesis and evaluation of antitumor cytotoxici-ty and caspase activation activity. J Enzyme Inhib Med Chem 2019,34(1),465-478","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e1800322","DOI":"10.1002\/cbdv.201800322","volume":"15","author":"Huan L.C.","year":"2018","unstructured":"Huan L.C.; Truc, L.C.; Phuong, C.V.; Hai, P-T.; Huong, L-T-T.; Linh, N.T.P.; Thuan, N.T.; Park, E.J.; Choi, Y.J.; Kang, J.S.; Han, S-B.; Nam, N-H.; Tran, P-T. N\u2032-[(E)-Arylidene]-2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-acetohydrazides: Synthesis and Evaluation of Caspase Activation Activity and Cytotoxicity. Chem Biodivers 2018,15(10),e1800322","journal-title":"Chem Biodivers"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e28487","DOI":"10.1371\/journal.pone.0028487","volume":"6","author":"Guo W.","year":"2011","unstructured":"Guo W.; Wu S.; Wang L.; Wei X.; Liu X.; Wang J.; Lu Z.; Hollingshead M.; Fang B.; Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS One 2011,6(12),e28487","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"Skehan P.","year":"1990","unstructured":"Skehan P.; Storeng R.; Scudiero D.; Monks A.; McMahon J.; Vistica D.; Warren J.T.; Bokesch H.; Kenney S.; Boyd M.R.; New color-imetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990,82(13),1107-1112","journal-title":"J Natl Cancer Inst"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2174\/1573406411666150702130633","volume":"11","author":"Dung T.M.","year":"2015","unstructured":"Dung T.M.; Dung P.T.; Oanh D.T.; Hai P.T.; Huong T.T.; Loi V.D.; Hahn H.; Han B.W.; Kim J.; Han S.B.; Nam N.H.; Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as his-tone deacetylase inhibitors and antitumor agents. Med Chem 2015,11(8),725-735","journal-title":"Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bioorg.2017.12.007","volume":"76","author":"Hieu D.T.","year":"2018","unstructured":"Hieu D.T.; Anh D.T.; Tuan N.M.; Hai P-T.; Huong L-T-T.; Kim J.; Kang J.S.; Vu T.K.; Dung P.T.P.; Han S-B.; Nam N-H.; Hoa N-D.; Design, synthesis and evaluation of novel N-hydroxybenzamides\/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and anti-tumor agents. Bioorg Chem 2018,76,258-267","journal-title":"Bioorg Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/S0960-894X(02)00758-8","volume":"12","author":"Kim Y.","year":"2002","unstructured":"Kim Y.; You Y-J.; Nam N-H.; Ahn B-Z.; Prodrugs of 4# - demethyl-4-deoxypodophyllotoxin: Synthesis and evaluation of the antitumor activity. Bioorg Med Chem Lett 2002,12(23),3435-3438","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=27","first-page":"3029","volume":"52","author":"Wu L.","year":"1992","unstructured":"Wu L.; Smythe A.M.; Stinson S.F.; Mullendore L.A.; Monks A.; Scudiero D.A.; Paull K.D.; Koutsoukos A.D.; Rubinstein L.V.; Boyd M.R.; Shoemaker R.H.; Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anti-cancer drug screening. Cancer Res 1992,52(11),3029-3034","journal-title":"Cancer Res"},{"year":"2009","unstructured":"Molecular Operating Environment (MOE); Chemical computing  group ULC: 1010 Sherbooke St. West, Suite #910, Montreal, QC,  Canada, H3A 2R7 2009","key":"ref=28"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"36000","DOI":"10.1074\/jbc.M112.397752","volume":"287","author":"Vel\u00e1zquez-Delgado E.M.","year":"2012","unstructured":"Vel\u00e1zquez-Delgado E.M.; Hardy J.A.; Zinc-mediated allosteric inhibition of caspase-6. J Biol Chem 2012,287(43),36000-36011","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"Pettersen E.F.","year":"2004","unstructured":"Pettersen E.F.; Goddard T.D.; Huang C.C.; Couch G.S.; Green-blatt D.M.; Meng E.C.; Ferrin T.E.; UCSF Chimera--a visualiza-tion system for exploratory research and analysis. J Comput Chem 2004,25(13),1605-1612","journal-title":"J Comput Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"Xiong G.","year":"2021","unstructured":"Xiong G.; Wu Z.; Yi J.; Fu L.; Yang Z.; Hsieh C.; Yin M.; Zeng X.; Wu C.; Lu A.; Chen X.; Hou T.; Cao D.; ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 2021,49(W1),W5-W14","journal-title":"Nucleic Acids Res"},{"key":"ref=32","first-page":"2209","volume":"18","author":"Hai P-T.","year":"2018","unstructured":"Hai P-T.; Miguel \u00c1.; C.-P.; Nguyen-Hai, N.; Juan, A.C.-G.; Bakh-tiyor, R.; Huong, L.-T.-T.; Gerardo, M. C.-M. In silico assessment of ADME properties: Advances in Caco-2 cell monolayer permea-bility modeling. Curr Top Med Chem 2018,18,2209-2229","journal-title":"Curr Top Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/bdd.2152","volume":"39","author":"Cabrera-P\u00e9rez M.\u00c1.","year":"2018","unstructured":"Cabrera-P\u00e9rez M.\u00c1.; Pham-The H.; Cervera M.F.; Hern\u00e1ndez-Armengol R.; Miranda-P\u00e9rez de Alejo C.; Brito-Ferrer Y.; Inte-grating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines. Biopharm Drug Dispos 2018,39(7),354-368","journal-title":"Biopharm Drug Dispos"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Exper-imental and computational approaches to estimate solubility and perme-ability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"104724","DOI":"10.1016\/j.yrtph.2020.104724","volume":"116","author":"Silva M.H.","year":"2020","unstructured":"Silva M.H.; Use of computational toxicology (CompTox) tools to predict in vivo toxicity for risk assessment. Regul Toxicol Pharmacol 2020,116,104724","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1021\/jm0492002","volume":"48","author":"Martin Y.C.","year":"2005","unstructured":"Martin Y.C.; A bioavailability score. J Med Chem 2005,48(9),3164-3170","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.tet.2012.12.031","volume":"69","author":"\u0160pul\u00e1k M.","year":"2013","unstructured":"\u0160pul\u00e1k M.; Nov\u00e1k Z.; Pal\u00e1t K.; Kune\u0161 J.; Pourov\u00e1 J.; Pour M.; The unambiguous synthesis and NMR assignment of 4-alkoxy and 3-alkylquinazolines. Tetrahedron 2013,69,1705-1711","journal-title":"Tetrahedron"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.bmc.2003.10.060","volume":"12","author":"Nam N-H.","year":"2004","unstructured":"Nam N-H.; Pitts R.L.; Sun G.; Sardari S.; Tiemo A.; Xie M.; Yan B.; Parang K.; Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg Med Chem 2004,12(4),779-787","journal-title":"Bioorg Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/BF02980153","volume":"27","author":"Nam N-H.","year":"2004","unstructured":"Nam N-H.; Hong D-H.; You Y-J.; Kim Y.; Bang S-C.; Kim H-M.; Ahn B-Z.; Synthesis and cytotoxicity of 2,5-dihydroxychalcones and related compounds. Arch Pharm Res 2004,27(6),581-588","journal-title":"Arch Pharm Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1055\/s-2004-835846","volume":"70","author":"Min B-S.","year":"2004","unstructured":"Min B-S.; Huong H-T-T.; Kim J-H.; Jun H-J.; Na M-K.; Nam N-H.; Lee H-K.; Bae K.; Kang S-S.; Furo-1,2-naphthoquinones from Crataegus pinnatifida with ICAM-1 expression inhibition ac-tivity. Planta Med 2004,70(12),1166-1169","journal-title":"Planta Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.18632\/oncotarget.6505","volume":"7","author":"Sarkar A.","year":"2016","unstructured":"Sarkar A.; Balakrishnan K.; Chen J.; Patel V.; Neelapu S.S.; McMurray J.S.; Gandhi V.; Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 2016,7(3),3461-3476","journal-title":"Oncotarget"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jmb.2009.03.003","volume":"388","author":"Peterson Q.P.","year":"2009","unstructured":"Peterson Q.P.; Goode D.R.; West D.C.; Ramsey K.N.; Lee J.J.; Hergenrother P.J.; PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J Mol Biol 2009,388(1),144-158","journal-title":"J Mol Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","volume":"18","author":"Hughes J.D.","year":"2008","unstructured":"Hughes J.D.; Blagg J.; Price D.A.; Bailey S.; Decrescenzo G.A.; Devraj R.V.; Ellsworth E.; Fobian Y.M.; Gibbs M.E.; Gilles R.W.; Greene N.; Huang E.; Krieger-Burke T.; Loesel J.; Wager T.; Whiteley L.; Zhang Y.; Physiochemical drug properties associ-ated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008,18(17),4872-4875","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2174\/1573406413666170209124302","volume":"13","author":"Castillo-Garit J.A.","year":"2017","unstructured":"Castillo-Garit J.A.; Casanola-Martin G.M.; Le-Thi-Thu H.; Pham-The H.; Barigye S.J.; A simple method to predict blood-brain barrier permeability of drug- like compounds using classifica-tion trees. Med Chem 2017,13(7),664-669","journal-title":"Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-816434-1.00001-2","author":"Turner A.P.","year":"2020","unstructured":"Turner A.P.; Alam C.; Bendayan R.;  Academic Press 2020","journal-title":"Academic Press"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","volume":"92","author":"Vandenberg J.I.","year":"2012","unstructured":"Vandenberg J.I.; Perry M.D.; Perrin M.J.; Mann S.A.; Ke Y.; Hill A.P.; hERG K(+) channels: Structure, function, and clinical signifi-cance. Physiol Rev 2012,92(3),1393-1478","journal-title":"Physiol Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopen.2018.05.001","volume":"7","author":"Larigot L.","year":"2018","unstructured":"Larigot L.; Juricek L.; Dairou J.; Coumoul X.; AhR signaling pathways and regulatory functions. Biochim Open 2018,7,1-9","journal-title":"Biochim Open"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220118154914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200345\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220118154914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T14:46:01Z","timestamp":1691678761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200345\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":47,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520622666220118154914","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}